Moreover, EGFR and carcinoembryonic antigen (CEA) are FDA-cleared colorectal cancer biomarkers for therapy monitoring, diagnosis, prognosis, and hepatic metastases screening (Spano et al., 2005). The gene discussed is CEACAM5; the disease is colorectal cancer.